251456-60-7 | 4-(Dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	97%	in stock	$84.00	$59.00
10mg	97%	in stock	$156.00	$109.00
20mg	97%	in stock	$254.00	$178.00

Description

• Catalog Number: AB27610
• Chemical Name: 4-(Dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide
• CAS Number: 251456-60-7
• Molecular Formula: C16H25N3O3
• Molecular Weight: 307.388
• MDL Number: MFCD03453554
• SMILES: ONC(=O)CCCCCCNC(=O)c1ccc(cc1)N(C)C
• NSC Number: 718169

Computed Properties

• Complexity: 340
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 9
• XLogP3: 1.7

Literature

• The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.

  Antimicrobial agents and chemotherapy 20170801

• Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

  Oncotarget 20160906

• Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.

  The Journal of international medical research 20160801

• Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.

  Transplantation 20160801

• Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling.

  Neurotoxicology 20150901

• Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.

  Cancer letters 20140828

• Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.

  Journal of natural products 20131122

• Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.

  Toxicology 20131004

• Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

  Molecular cancer therapeutics 20130801

• Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors.

  Epigenomics 20130801

• A genomic approach to predict synergistic combinations for breast cancer treatment.

  The pharmacogenomics journal 20130201

• SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition.

  PloS one 20130101

• Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

  Investigational new drugs 20121201

• Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

  Molecular pharmacology 20121201

• The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.

  Bioorganic & medicinal chemistry letters 20121201

• Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.

  The Journal of biological chemistry 20121102

• Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase.

  European journal of cancer (Oxford, England : 1990) 20121101

• Histone deacetylase inhibitors preserve function in aging axons.

  Journal of neurochemistry 20121101

• Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101

• Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

  International journal of cancer 20121015

• Induced production of mycotoxins in an endophytic fungus from the medicinal plant Datura stramonium L.

  Bioorganic & medicinal chemistry letters 20121015

• Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.

  The Journal of dermatology 20121001

• Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

  Journal of pharmaceutical sciences 20121001

• Curbing autophagy and histone deacetylases to kill cancer cells.

  Autophagy 20121001

• Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

  Epigenetics 20121001

• Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20121001

• Use of reprogrammed cells to identify therapy for respiratory papillomatosis.

  The New England journal of medicine 20120927

• Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

  International journal of cancer 20120915

• Efficacy and safety of suberoylanilide hydroxamic acid (Vorinostat) in the treatment of canine corneal fibrosis.

  Veterinary ophthalmology 20120901

• Early prediction of response to Vorinostat in an orthotopic rat glioma model.

  NMR in biomedicine 20120901

• Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.

  American journal of hematology 20120901

• Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability.

  Toxicology and applied pharmacology 20120901

• Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

  Breast cancer research and treatment 20120901

• HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

  Nature neuroscience 20120901

• Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

  Cell cycle (Georgetown, Tex.) 20120901

• SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.

  Cellular & molecular immunology 20120901

• Creating a 'pro-survival' phenotype through epigenetic modulation.

  Surgery 20120901

• [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20120901

• Cancer research: Open ambition.

  Nature 20120809

• Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.

  Leukemia & lymphoma 20120801

• Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

  Cell death and differentiation 20120801

• Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

• Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

• Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma.

  Molecular cancer research : MCR 20120801

• HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.

  Anticancer research 20120801

• REST is a novel prognostic factor and therapeutic target for medulloblastoma.

  Molecular cancer therapeutics 20120801

• [Novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): facilitating fear extinction].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20120801

• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

  Nature 20120726

• Scientists investigate routing latent HIV from its reservoirs to achieve a cure.

  JAMA 20120725

• HIV: Shock and kill.

  Nature 20120725

• Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

  Circulation 20120724

• Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.

  International journal of radiation oncology, biology, physics 20120715

• Histone deacetylase inhibitors induce mitochondrial elongation.

  Journal of cellular physiology 20120701

• SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.

  Pathology oncology research : POR 20120701

• Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.

  Oncology reports 20120701

• Selenium-containing histone deacetylase inhibitors for melanoma management.

  Cancer biology & therapy 20120701

• Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

  Anticancer research 20120701

• Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620

• Growth stimulating effect on queen bee larvae of histone deacetylase inhibitors.

  Journal of agricultural and food chemistry 20120620

• Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.

  Oncogene 20120614

• Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

  Hepatology (Baltimore, Md.) 20120601

• Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.

  Leukemia 20120601

• Repression of PDGF-R-α after cellular injury involves TNF-α, formation of a c-Fos-YY1 complex, and negative regulation by HDAC.

  American journal of physiology. Cell physiology 20120601

• Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure.

  Neurotoxicology 20120601

• Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.

  Leukemia research 20120601

• Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.

  Biomaterials 20120601

• Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

  Cancer biology & therapy 20120601

• Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.

  Leukemia research 20120601

• Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.

  Journal of pediatric surgery 20120601

• Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.

  Blood 20120531

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.

  Leukemia & lymphoma 20120501

• Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.

  Haematologica 20120501

• Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

  European journal of cancer (Oxford, England : 1990) 20120501

• Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

  Biochemical pharmacology 20120501

• Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.

  International journal of oncology 20120501

• Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene.

  Journal of psychiatric research 20120501

• Suberoylanilide hydroxamic acid enhances odontoblast differentiation.

  Journal of dental research 20120501

• Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.

  Journal of immunology (Baltimore, Md. : 1950) 20120501

• Efficacy of vorinostat in a murine model of polycythemia vera.

  Blood 20120419

• MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.

  Cell cycle (Georgetown, Tex.) 20120415

• Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.

  Biochemical and biophysical research communications 20120406

• Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.

  Investigational new drugs 20120401

• Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

  BJU international 20120401

• Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.

  Breast cancer research and treatment 20120401

• Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.

  International immunopharmacology 20120401

• Vorinostat: a potent agent to prevent and treat laser-induced corneal haze.

  Journal of refractive surgery (Thorofare, N.J. : 1995) 20120401

• CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.

  Epigenetics 20120401

• Novel therapeutics in multiple myeloma.

  Hematology (Amsterdam, Netherlands) 20120401

• A case of Sweet's syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma.

  Cutaneous and ocular toxicology 20120301

• A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.

  Cancer chemotherapy and pharmacology 20120301

• Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells.

  Cancer letters 20120227

• Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

  Journal of medicinal chemistry 20120223

• Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation.

  The Journal of biological chemistry 20120210

• Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

  Oncogene 20120202

• Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

  Investigational new drugs 20120201

• Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

  Investigational new drugs 20120201

• A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

  Leukemia & lymphoma 20120201

• SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.

  Biochimie 20120201

• Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.

  International journal of molecular medicine 20120201

• Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

  Neuro-oncology 20120201

• Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.

  Journal of leukocyte biology 20120201

• Role for Class I histone deacetylases in multidrug resistance.

  Experimental cell research 20120201

• Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120201

• Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.

  The journal of trauma and acute care surgery 20120201

• Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

• Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.

  Bioorganic & medicinal chemistry 20120115

• Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

  British journal of cancer 20120103

• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage.

  British journal of pharmacology 20120101

• Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.

  Neuro-oncology 20120101

• HDAC inhibitors in HIV.

  Immunology and cell biology 20120101

• HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.

  Immunology and cell biology 20120101

• Emerging therapies in hematopoietic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120101

• Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.

  PloS one 20120101

• Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors.

  PloS one 20120101

• In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.

  Radiation oncology (London, England) 20120101

• Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors.

  PloS one 20120101

• Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.

  BMC cancer 20120101

• Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts.

  PloS one 20120101

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ.

  Journal of neuroinflammation 20120101

• QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.

  Cardiology journal 20120101

• The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.

  PloS one 20120101

• A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

  PloS one 20120101

• Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.

  PloS one 20120101

• Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

  Radiation oncology (London, England) 20120101

• [Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].

  Biofizika 20120101

• Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.

  Bioorganic & medicinal chemistry letters 20111215

• Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.

  Journal of cellular physiology 20111201

• SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

  Cell death and differentiation 20111201

• Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.

  Oral oncology 20111201

• A new target for personalized medicine.

  EMBO reports 20111201

• miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.

  The Journal of biological chemistry 20111125

• Reversible molecular pathology of skeletal muscle in spinal muscular atrophy.

  Human molecular genetics 20111115

• Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.

  Toxicology and applied pharmacology 20111115

• Determination of HS270, a new histone deacetylase inhibitor, in rat plasma by LC-MS/MS--application to a preclinical pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115

• Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents.

  Molecules (Basel, Switzerland) 20111102

• Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.

  Breast cancer research and treatment 20111101

• STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction.

  Inflammatory bowel diseases 20111101

• A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.

  The European respiratory journal 20111101

• Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.

  Journal of neuro-oncology 20111101

• Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.

  Pharmacogenetics and genomics 20111101

• A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.

  Acta neuropathologica 20111101

• HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.

  Journal of lipid research 20111101

• Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer.

  Current clinical pharmacology 20111101

• p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.

  The Journal of biological chemistry 20111028

• The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

  Bioorganic & medicinal chemistry letters 20111015

• Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.

  Journal of controlled release : official journal of the Controlled Release Society 20111010

• Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

  Molecular pharmaceutics 20111003

• A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

  Investigational new drugs 20111001

• Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

  Cancer 20111001

• Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells.

  Journal of cellular biochemistry 20111001

• Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.

  American journal of physiology. Cell physiology 20111001

• MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.

  Biomaterials 20111001

• SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.

  Proteomics 20111001

• Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.

  Epigenetics 20111001

• Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.

  Anticancer research 20111001

• Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.

  The Journal of biological chemistry 20110930

• Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

  Lung cancer (Amsterdam, Netherlands) 20110901

• Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.

  Leukemia & lymphoma 20110901

• HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

  Journal of cellular physiology 20110901

• HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.

  Apoptosis : an international journal on programmed cell death 20110901

• Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.

  European journal of medicinal chemistry 20110901

• Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.

  Human reproduction (Oxford, England) 20110901

• Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

  Molecular cancer therapeutics 20110901

• Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.

  Proteomics 20110901

• Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.

  Leukemia & lymphoma 20110901

• Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock.

  Surgery 20110901

• Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

  Journal of medicinal chemistry 20110811

• In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).

  Journal of medicinal chemistry 20110811

• Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

  Cancer chemotherapy and pharmacology 20110801

• Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.

  Pancreas 20110801

• Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.

  Oncology reports 20110801

• Structure-based optimization of click-based histone deacetylase inhibitors.

  European journal of medicinal chemistry 20110801

• Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801

• Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.

  Neuro-oncology 20110801

• [Development of novel agents for multiple myeloma; now and the future].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• [Present status and perspective of targeted therapy for B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• Epigenetic treatment of neurological disease.

  Epigenomics 20110801

• Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

  Cancer letters 20110728

• Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth.

  Vaccine 20110726

• Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.

  Cancer gene therapy 20110701

• The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

  Nuclear medicine and biology 20110701

• [Epigenetic therapy in myelodysplastic syndromes].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701

• Efficient organic monoliths prepared by γ-radiation induced polymerization in the evaluation of histone deacetylase inhibitors by capillary(nano)-high performance liquid chromatography and ion trap mass spectrometry.

  Journal of chromatography. A 20110624

• Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

  British journal of cancer 20110607

• Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.

  Neuropathology and applied neurobiology 20110601

• Leukemia cutis in association With Grover's disease.

  The American Journal of dermatopathology 20110601

• Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor.

  Kidney international 20110601

• Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes.

  Journal of inorganic biochemistry 20110601

• Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

  Cancer research 20110601

• Metabolism as a key to histone deacetylase inhibition.

  Critical reviews in biochemistry and molecular biology 20110601

• HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

  Molecular cancer research : MCR 20110601

• Clinical development of panobinostat in classical Hodgkin's lymphoma.

  Expert review of hematology 20110601

• Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.

  Cancer research 20110515

• Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.

  The Journal of biological chemistry 20110506

• Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.

  Bone 20110501

• Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

  The American journal of pathology 20110501

• Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110401

• Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.

  Molecular and cellular biochemistry 20110401

• The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

  British journal of pharmacology 20110401

• Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.

  Cancer science 20110401

• KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.

  Oncology reports 20110401

• Differentiation of NUT midline carcinoma by epigenomic reprogramming.

  Cancer research 20110401

• The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.

  Journal of drugs in dermatology : JDD 20110401

• Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320

• Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

  British journal of cancer 20110315

• Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).

  Cancer chemotherapy and pharmacology 20110301

• Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation.

  Leukemia 20110301

• HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.

  International journal of oncology 20110301

• 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.

  The Journal of steroid biochemistry and molecular biology 20110301

• [Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110301

• Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.

  The Journal of biological chemistry 20110225

• Histone deacetylase inhibitors as a tool to up-regulate new fungal biosynthetic products: isolation of EGM-556, a cyclodepsipeptide, from Microascus sp.

  Organic letters 20110204

• Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.

  Expert opinion on investigational drugs 20110201

• Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events.

  Neuron 20110127

• Coumarin-suberoylanilide hydroxamic acid as a fluorescent probe for determining binding affinities and off-rates of histone deacetylase inhibitors.

  Analytical biochemistry 20110115

• Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.

  Biochemical and biophysical research communications 20110107

• Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.

  Breast cancer research and treatment 20110101

• Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.

  Neoplasma 20110101

• Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.

  Molecular medicine (Cambridge, Mass.) 20110101

• Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.

  Radiation oncology (London, England) 20110101

• Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.

  Oncology research 20110101

• Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.

  BMC neuroscience 20110101

• Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells.

  PloS one 20110101

• Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.

  PloS one 20110101

• The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.

  PloS one 20110101

• Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.

  PloS one 20110101

• Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.

  Radiation oncology (London, England) 20110101

• Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.

  Oxidative medicine and cellular longevity 20110101

• SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

  PloS one 20110101

• In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).

  BMC bioinformatics 20110101

• Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

  Blood 20101223

• Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

  Journal of cancer research and clinical oncology 20101201

• Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.

  Annals of surgical oncology 20101201

• A novel xenograft model of cutaneous T-cell lymphoma.

  Experimental dermatology 20101201

• Inhibition of class IIb histone deacetylase significantly improves cloning efficiency in mice.

  Biology of reproduction 20101201

• Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.

  Gynecologic oncology 20101201

• The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.

  Molecular cancer therapeutics 20101201

• Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.

  Molecular cancer therapeutics 20101201

• Poikilodermatous mycosis fungoides.

  Dermatology online journal 20101115

• Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells.

  Journal of cellular physiology 20101101

• Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells.

  Pancreas 20101101

• Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.

  Annals of hematology 20101101

• In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?

  Gynecologic oncology 20101101

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

  Cancer chemotherapy and pharmacology 20101101

• Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.

  Oncology reports 20101101

• Synergistic killing effect between vorinostat and target of CD146 in malignant cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101101

• Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.

  Autophagy 20101101

• Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line.

  Experimental biology and medicine (Maywood, N.J.) 20101101

• Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

  British journal of cancer 20101101

• Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

  British journal of cancer 20101026

• Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

  Blood 20101021

• Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.

  Blood 20101014

• Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.

  Oncogene 20101014

• Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010

• Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

  Journal of cellular and molecular medicine 20101001

• Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.

  Apoptosis : an international journal on programmed cell death 20101001

• Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition.

  Brain research 20101001

• Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.

  Anti-cancer drugs 20101001

• Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.

  Molecular cancer therapeutics 20101001

• The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.

  Autophagy 20101001

• A pharmacogenetic study of vorinostat glucuronidation.

  Pharmacogenetics and genomics 20101001

• Solubilization of vorinostat by cyclodextrins.

  Journal of clinical pharmacy and therapeutics 20101001

• HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2.

  Aging 20101001

• Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions.

  Cancer letters 20100928

• Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.

  Journal of neuro-oncology 20100901

• Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures.

  Biomaterials 20100901

• Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock.

  The Journal of surgical research 20100901

• Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.

  Urology 20100901

• Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.

  International journal of radiation oncology, biology, physics 20100901

• Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

• Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

  Proceedings of the National Academy of Sciences of the United States of America 20100817

• A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor.

  The Journal of biological chemistry 20100813

• Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

  The Journal of clinical investigation 20100802

• The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.

  Cancer chemotherapy and pharmacology 20100801

• Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.

  Rheumatology (Oxford, England) 20100801

• The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100801

• Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells.

  Autophagy 20100801

• Surviving lethal septic shock without fluid resuscitation in a rodent model.

  Surgery 20100801

• Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.

  International journal of oncology 20100801

• Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801

• Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.

  Cancer research 20100801

• Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.

  Cancer prevention research (Philadelphia, Pa.) 20100801

• Serine proteases in histone deacetylase inhibitor-induced apoptosis.

  Molecular cancer therapeutics 20100801

• Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

  Molecular cancer therapeutics 20100801

• An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor.

  Archives of pharmacal research 20100801

• A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100715

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.

  Haematologica 20100701

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.

  Cardiovascular research 20100701

• A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

  British journal of haematology 20100701

• Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture.

  Cancer letters 20100628

• Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function .

  Biochemistry 20100622

• The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

  Blood 20100603

• Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.

  Journal of leukocyte biology 20100601

• Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).

  Pharmaceutical research 20100601

• Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.

  Cancer science 20100601

• Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.

  Cancer research 20100601

• Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.

  Cancer 20100601

• Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.

  Cell cycle (Georgetown, Tex.) 20100601

• Targeting histone deacetylases: development of vorinostat for the treatment of cancer.

  Epigenomics 20100601

• Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.

  International journal of cancer 20100515

• Histone deacetylase inhibitors: Are they here to stay?

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515

• Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515

• Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.

  The Lancet. Oncology 20100501

• Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.

  The Journal of thoracic and cardiovascular surgery 20100501

• [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].

  Pharmazie in unserer Zeit 20100501

• SAHA and curcumin combinations co-enhance histone acetylation in human cancer cells but operate antagonistically in exerting cytotoxic effects.

  Journal of Asian natural products research 20100501

• [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100501

• Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.

  Journal of medicinal chemistry 20100422

• SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.

  Human molecular genetics 20100415

• Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100415

• Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.

  ChemMedChem 20100406

• Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

  Breast cancer research and treatment 20100401

• A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

  Cancer chemotherapy and pharmacology 20100401

• Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

  Haematologica 20100401

• Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.

  British journal of pharmacology 20100401

• Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.

  International journal of oncology 20100401

• The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.

  Clinical lymphoma, myeloma & leukemia 20100401

• Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.

  Clinical lymphoma, myeloma & leukemia 20100401

• Emerging role of epigenetic therapies in cutaneous T-cell  lymphomas.

  Expert review of hematology 20100401

• The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

  Blood 20100325

• SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.

  Bioorganic & medicinal chemistry letters 20100315

• Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.

  Journal of medicinal chemistry 20100311

• Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100301

• Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

  European journal of haematology 20100301

• Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100301

• The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.

  Cellular and molecular life sciences : CMLS 20100301

• Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells.

  Proteomics 20100301

• Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.

  Leukemia 20100301

• SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

  Molecular cancer therapeutics 20100301

• Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

  International journal of cancer 20100201

• Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells.

  American journal of physiology. Renal physiology 20100201

• Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

  The Journal of clinical endocrinology and metabolism 20100201

• Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100201

• Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair.

  International journal of radiation oncology, biology, physics 20100201

• Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.

  Chemistry & biology 20100129

• Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

  Oncogene 20100107

• Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.

  Cancer science 20100101

• Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.

  Gynecologic oncology 20100101

• Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

  International journal of toxicology 20100101

• Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin.

  Journal of cellular biochemistry 20100101

• Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100101

• HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity.

  Oncology reports 20100101

• Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.

  Nature chemical biology 20100101

• Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• The saving switch.

  Nature medicine 20100101

• Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.

  Neoplasia (New York, N.Y.) 20100101

• Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.

  Molecular cancer 20100101

• Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.

  Cancer cell international 20100101

• Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells.

  Journal of biomedical science 20100101

• Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.

  Proteomics. Clinical applications 20100101

• Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.

  Cancer 20091201

• MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.

  International journal of oncology 20091201

• New patented histone deacetylase inhibitors.

  Expert opinion on therapeutic patents 20091201

• Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

  Clinical lymphoma & myeloma 20091201

• Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

• New treatment strategy enhances outcome for lung cancer.

  Cancer biology & therapy 20091201

• A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

• Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.

  Cancer chemotherapy and pharmacology 20091101

• Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents.

  Shock (Augusta, Ga.) 20091101

• Response of an adult patient with pineoblastoma to vorinostat and retinoic acid.

  Journal of neuro-oncology 20091101

• Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.

  Molecular and biochemical parasitology 20091101

• Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.

  European journal of cancer (Oxford, England : 1990) 20091101

• Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

  Molecular cancer therapeutics 20091101

• Leukonychia related to vorinostat.

  Archives of dermatology 20091101

• Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene.

  Journal of molecular biology 20091023

• Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells.

  Experimental cell research 20091015

• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

  British journal of cancer 20091006

• Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.

  The Journal of pharmacology and experimental therapeutics 20091001

• Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.

  Leukemia 20091001

• A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.

  Anti-cancer drugs 20091001

• Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• A phase 2 study of vorinostat in acute myeloid leukemia.

  Haematologica 20091001

• Antidepressant actions of histone deacetylase inhibitors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090916

• SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells.

  Chemico-biological interactions 20090914

• Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

  Oncogene 20090903

• Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.

  Breast cancer research and treatment 20090901

• Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.

  Oral oncology 20090901

• Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

  Investigative ophthalmology & visual science 20090901

• Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

  Pediatric blood & cancer 20090901

• Chemical induction of silent biosynthetic pathway transcription in Aspergillus niger.

  Journal of industrial microbiology & biotechnology 20090901

• KLF4 suppresses HDACi induced caspase activation and the SAPK pathway by targeting p57(Kip2).

  Apoptosis : an international journal on programmed cell death 20090901

• Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.

  European journal of cancer (Oxford, England : 1990) 20090901

• Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

  Cancer science 20090901

• MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.

  International journal of oncology 20090901

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.

  European journal of cancer (Oxford, England : 1990) 20090901

• Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

  AIDS research and human retroviruses 20090901

• Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

  Cancer research 20090901

• Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression.

  Molecular cancer therapeutics 20090901

• Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.

  Archives of dermatology 20090901

• The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation.

  Free radical biology & medicine 20090815

• Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.

  Cancer research 20090815

• Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090815

• Lysine acetylation targets protein complexes and co-regulates major cellular functions.

  Science (New York, N.Y.) 20090814

• MeCP2 function in the basolateral amygdala in Rett syndrome.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090812

• Development of vorinostat: current applications and future perspectives for cancer therapy.

  Cancer letters 20090808

• HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.

  Cancer letters 20090808

• Histone deacetylase inhibitors as anti-neoplastic agents.

  Cancer letters 20090808

• The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.

  Leukemia 20090801

• Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.

  Molecular pharmacology 20090801

• HDAC inhibitor-based therapies and haematological malignancy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Histone modifier, the gatekeeper of good memory.

  Cell research 20090801

• Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.

  Annals of hematology 20090701

• Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?

  The European respiratory journal 20090701

• Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.

  Cancer biology & therapy 20090701

• Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

  Cancer biology & therapy 20090701

• Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.

  Cancer biology & therapy 20090701

• Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

  International journal of molecular medicine 20090701

• A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.

  Journal of the American Academy of Dermatology 20090701

• Clinical roundtable monograph. Combination therapies for MDS.

  Clinical advances in hematology & oncology : H&O 20090701

• Clinical studies of histone deacetylase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

• Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.

  Cancer chemotherapy and pharmacology 20090601

• An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes.

  International journal for parasitology 20090601

• Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.

  European journal of haematology 20090601

• Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

  Endocrine 20090601

• Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.

  Anti-cancer drugs 20090601

• Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.

  Bioorganic & medicinal chemistry letters 20090601

• Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.

  International journal of radiation oncology, biology, physics 20090601

• Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• American Association for Cancer Research 100th Annual Meeting.

  The Lancet. Oncology 20090601

• Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

  Molecular cancer therapeutics 20090601

• Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

  Molecular cancer therapeutics 20090601

• HDAC2 negatively regulates memory formation and synaptic plasticity.

  Nature 20090507

• Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells.

  Stem cells and development 20090501

• Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.

  Molecular pharmacology 20090501

• Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.

  Cancer biology & therapy 20090501

• Efficient continuous flow synthesis of hydroxamic acids and suberoylanilide hydroxamic acid preparation.

  The Journal of organic chemistry 20090501

• A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

• Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

  Blood 20090430

• Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090420

• Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

  The international journal of biochemistry & cell biology 20090401

• Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

  Cancer research 20090401

• Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain.

  Nuclear medicine and biology 20090401

• Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death.

  Cell biochemistry and function 20090401

• MeCP2-mediated transcription repression in the basolateral amygdala may underlie heightened anxiety in a mouse model of Rett syndrome.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090401

• Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090401

• Regulation of adipocyte differentiation by histone deacetylase inhibitors.

  Archives of pharmacal research 20090401

• HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling.

  The Journal of biological chemistry 20090320

• Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.

  Oncogene 20090319

• Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.

  The Journal of biological chemistry 20090313

• Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20090301

• Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells.

  Carcinogenesis 20090301

• Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090301

• Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.

  Blood 20090226

• Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells.

  International journal of cancer 20090215

• Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.

  Molecular cancer therapeutics 20090201

• Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

  AIDS research and human retroviruses 20090201

• The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20090201

• Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.

  Human molecular genetics 20090115

• Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

  The Journal of clinical endocrinology and metabolism 20090101

• Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues.

  Archives of pharmacal research 20090101

• Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors.

  Cellular immunology 20090101

• New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

  Journal of hematology & oncology 20090101

• Vorinostat in solid and hematologic malignancies.

  Journal of hematology & oncology 20090101

• DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

  BMC medical genomics 20090101

• Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.

  International immunopharmacology 20081220

• HDAC inhibition upregulates the expression of angiostatic ADAMTS1.

  FEBS letters 20081210

• Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells.

  Cancer letters 20081208

• Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo.

  Journal of leukocyte biology 20081201

• Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.

  Nature clinical practice. Oncology 20081201

• SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.

  The Journal of pathology 20081201

• Molecular biology and targeted therapy of cutaneous T-cell lymphomas.

  Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 20081201

• Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.

  Journal of biosciences 20081201

• Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.

  Breast cancer research and treatment 20081101

• Sensitization of RPE cells by alphaB-crystallin siRNA to SAHA-induced stage 1 apoptosis through abolishing the association of alphaB-crystallin with HDAC1 in SC35 speckles.

  Investigative ophthalmology & visual science 20081101

• A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.

  Proteins 20081001

• The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

  Critical reviews in oncology/hematology 20081001

• Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.

  Investigational new drugs 20081001

• Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

  Blood 20081001

• Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

  Blood 20081001

• HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2.

  Biochimica et biophysica acta 20081001

• Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.

  Cancer biology & therapy 20081001

• Treatment of cutaneous T-cell lymphoma: focus on vorinostat.

  Journal of the American Academy of Dermatology 20081001

• Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).

  International journal of oncology 20081001

• Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• [Epigenetics in hematological disorders].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities.

  ChemMedChem 20080901

• In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.

  International journal of pharmaceutics 20080901

• Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.

  Annals of surgical oncology 20080901

• Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.

  Cancer biology & therapy 20080901

• Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

• Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

  Journal of the American Chemical Society 20080820

• Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.

  Blood 20080815

• Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

  Blood 20080801

• The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.

  International journal of oncology 20080801

• Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans.

  Surgery 20080801

• Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.

  Oncogene 20080724

• Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.

  Statistics in medicine 20080720

• Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.

  Journal of proteome research 20080701

• Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

  The Journal of clinical investigation 20080701

• Isoform-selective histone deacetylase inhibitors.

  Chemical Society reviews 20080701

• Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.

  Oncology reports 20080701

• Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.

  American journal of veterinary research 20080701

• Targeted treatment and new agents in diffuse large B-cell lymphoma.

  Seminars in hematology 20080701

• Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.

  The Journal of pharmacology and experimental therapeutics 20080601

• Structural origin of selectivity in class II-selective histone deacetylase inhibitors.

  Journal of medicinal chemistry 20080522

• Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.

  Cancer research 20080515

• OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.

  Cancer research 20080515

• Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080515

• Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.

  Gut 20080501

• A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  Gynecologic oncology 20080501

• Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.

  Biochemical pharmacology 20080501

• Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.

  Molecular cancer therapeutics 20080501

• Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.

  Journal of the American Academy of Dermatology 20080501

• Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.

  Cancer chemotherapy and pharmacology 20080401

• Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).

  Journal of neuro-oncology 20080401

• Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.

  Experimental hematology 20080401

• Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.

  Cancer research 20080401

• Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

  Neoplasia (New York, N.Y.) 20080401

• MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

  Molecular cancer therapeutics 20080401

• HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.

  Proceedings of the National Academy of Sciences of the United States of America 20080325

• Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.

  Leukemia 20080301

• Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.

  Molecular pharmacology 20080301

• Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.

  Haematologica 20080301

• Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.

  Leukemia & lymphoma 20080301

• Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery.

  Current eye research 20080301

• Histone deacetylase inhibitors in lymphoma and solid malignancies.

  Expert review of anticancer therapy 20080301

• Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques.

  Transplantation proceedings 20080301

• Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes.

  Journal of the American Chemical Society 20080220

• Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).

  Bioorganic & medicinal chemistry 20080215

• Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080215

• Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.

  Leukemia research 20080201

• Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

  Investigational new drugs 20080201

• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  Blood 20080201

• Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

  European journal of haematology 20080201

• Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.

  Birth defects research. Part B, Developmental and reproductive toxicology 20080201

• Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1.

  The international journal of biochemistry & cell biology 20080101

• Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.

  International journal of oncology 20080101

• Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.

  Molecular cancer 20080101

• Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.

  Anticancer research 20080101

• Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor.

  Anticancer research 20080101

• FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20080101

• Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.

  Journal of medicinal chemistry 20071227

• Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment.

  Immunology 20071201

• Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.

  International journal of oncology 20071201

• Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.

  Endocrine-related cancer 20071201

• Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET.

  Cancer research 20071201

• Epigenetic regulation as a new target for breast cancer therapy.

  Cancer investigation 20071201

• Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.

  Molecular cancer therapeutics 20071201

• Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.

  Bioorganic & medicinal chemistry letters 20071115

• Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.

  Bioorganic & medicinal chemistry letters 20071115

• Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

  Journal of cancer research and clinical oncology 20071101

• Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.

  Molecular cancer therapeutics 20071101

• Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.

  Molecular cancer therapeutics 20071101

• Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.

  Blood 20071001

• Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

  Hepatology (Baltimore, Md.) 20071001

• Comment on developmental toxicity evaluation on Vorinostat and relationship with HDAC inhibition.

  Birth defects research. Part B, Developmental and reproductive toxicology 20071001

• Histone deacetylase inhibitor-induced glycodelin enhances the initial step of implantation.

  Human reproduction (Oxford, England) 20071001

• FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

  The oncologist 20071001

• Histone deacetylase inhibitors.

  Oncology (Williston Park, N.Y.) 20071001

• 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

  Journal of medicinal chemistry 20070906

• Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.

  Bioorganic & medicinal chemistry letters 20070901

• Trithiocarbonates: exploration of a new head group for HDAC inhibitors.

  Bioorganic & medicinal chemistry letters 20070901

• The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.

  International journal of oncology 20070901

• Histone deacetylase inhibitors selectively suppress expression of HDAC7.

  Molecular cancer therapeutics 20070901

• Vorinostat in cutaneous T-cell lymphoma.

  Drugs of today (Barcelona, Spain : 1998) 20070901

• Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.

  International journal of cancer 20070801

• Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

  Cell death and differentiation 20070801

• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720

• Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070715

• Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.

  Journal of neuro-oncology 20070701

• SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.

  Apoptosis : an international journal on programmed cell death 20070701

• Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.

  Blood 20070701

• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

  Expert opinion on investigational drugs 20070701

• A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.

  Journal of drugs in dermatology : JDD 20070701

• Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.

  Biochemical pharmacology 20070615

• Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070615

• Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.

  The journal of gene medicine 20070601

• Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.

  International journal of oncology 20070601

• Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver.

  Surgery 20070601

• Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.

  The Journal of parasitology 20070601

• Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.

  Bioorganic & medicinal chemistry letters 20070515

• Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.

  Cancer 20070515

• Discovery of epigenetically silenced genes in acute myeloid leukemias.

  Leukemia 20070501

• Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

  Cancer biology & therapy 20070501

• Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.

  International journal of oncology 20070501

• In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

  Biological & pharmaceutical bulletin 20070501

• Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.

  Bioorganic & medicinal chemistry letters 20070415

• Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070415

• Histone deacetylase inhibitors suppress natural killer cell cytolytic activity.

  FEBS letters 20070403

• Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment.

  Biochemical pharmacology 20070401

• Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

  British journal of pharmacology 20070401

• Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

  Haematologica 20070401

• [Histone deacetylase inhibitor SAHA induces inactivation of MAPK signaling and apoptosis in HL-60 cells].

  Zhongguo shi yan xue ye xue za zhi 20070401

• Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.

  Drug metabolism letters 20070401

• Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070328

• Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.

  The Medical letter on drugs and therapeutics 20070312

• In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.

  Gynecologic oncology 20070301

• Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.

  Bioorganic & medicinal chemistry letters 20070215

• Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.

  Endocrinology 20070201

• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.

  Birth defects research. Part B, Developmental and reproductive toxicology 20070201

• Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

  Molecular cancer therapeutics 20070201

• Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.

  Oncology (Williston Park, N.Y.) 20070201

• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  Blood 20070101

• Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.

  Scandinavian journal of gastroenterology 20070101

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070101

• HDAC inhibitors overcome first hurdle.

  Nature biotechnology 20070101

• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

  Nature biotechnology 20070101

• Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

  Molecular cancer therapeutics 20070101

• Vorinostat.

  Nature reviews. Drug discovery 20070101

• c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.

  The international journal of biochemistry & cell biology 20070101

• New skin cancer drug.

  FDA consumer 20070101

• Modulating autophagy for therapeutic benefit.

  Autophagy 20070101

• HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.

  The international journal of biochemistry & cell biology 20070101

• Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells.

  The international journal of biochemistry & cell biology 20070101

• Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.

  Molecular pharmacology 20061201

• A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061201

• Treatment of cutaneous T-cell lymphoma/mycosis fungoides.

  Dermatology nursing 20061201

• Stability studies of vorinostat and its two metabolites in human plasma, serum and urine.

  Journal of pharmaceutical and biomedical analysis 20061116

• Vorinostat approved for rare lymphoma.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115

• Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.

  Oncology reports 20061101

• Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65.

  The Journal of biological chemistry 20061020

• Epigenetic cancer therapy makes headway.

  Journal of the National Cancer Institute 20061018

• Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.

  Bioorganic & medicinal chemistry letters 20060915

• Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.

  Cancer research 20060915

• Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060915

• Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.

  Journal of neuro-oncology 20060901

• Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060901

• A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060818

• The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

  International journal of cancer 20060815

• Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.

  Blood 20060815

• The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.

  Human genetics 20060801

• Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.

  Molecular cancer therapeutics 20060801

• SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.

  International journal of cancer 20060701

• Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.

  Experimental hematology 20060601

• Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.

  Bioorganic & medicinal chemistry 20060515

• Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.

  Cancer research 20060515

• Histone hyperacetylation is associated with amelioration of experimental colitis in mice.

  Journal of immunology (Baltimore, Md. : 1950) 20060415

• Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.

  The Journal of biological chemistry 20060414

• Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.

  Oncogene 20060406

• M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.

  Gynecologic oncology 20060401

• Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

  Cancer research 20060401

• Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer.

  Journal of the National Cancer Institute 20060315

• Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.

  The Journal of biological chemistry 20060303

• Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

  International journal of oncology 20060301

• Human endometrial cytodifferentiation by histone deacetylase inhibitors.

  Human cell 20060201

• SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

  Oncology reports 20060101

• Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

  European journal of haematology 20060101

• Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

  Clinical lung cancer 20060101

• Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.

  BMC cancer 20060101

• Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

  BMC cancer 20060101

• Histone deacetylase inhibitors in cancer therapy.

  Cancer investigation 20060101

• Molecule of the month. Vorinostat.

  Drug news & perspectives 20060101

• Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.

  Anticancer research 20060101

• Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.

  Endocrinology 20051201

• Crystal structure of a bacterial class 2 histone deacetylase homologue.

  Journal of molecular biology 20051118

• Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.

  Cancer research 20051101

• Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.

  The Journal of investigative dermatology 20051101

• Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

  Leukemia 20051001

• Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.

  The Journal of biological chemistry 20050923

• Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.

  Leukemia 20050901

• Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.

  Cancer research 20050901

• Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.

  Clinical prostate cancer 20050901

• It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.

  Cancer research 20050801

• Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.

  Molecular cancer therapeutics 20050801

• Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.

  Apoptosis : an international journal on programmed cell death 20050801

• Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.

  Surgery 20050801

• A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.

  Journal of medicinal chemistry 20050728

• Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.

  Bioorganic & medicinal chemistry 20050701

• Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

  Molecular and cellular biology 20050701

• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050610

• The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.

  Journal of cancer research and clinical oncology 20050601

• Novel histone deacetylase inhibitors in the treatment of thyroid cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

• The role of histone acetylation in SMN gene expression.

  Human molecular genetics 20050501

• Modulation of radiation response by histone deacetylase inhibition.

  International journal of radiation oncology, biology, physics 20050501

• Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.

  Journal of neurochemistry 20050501

• Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.

  Molecular pharmacology 20050401

• Histone deacetylase inhibitors in programmed cell death and cancer therapy.

  Cell cycle (Georgetown, Tex.) 20050401

• Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.

  Cancer research 20050315

• [Histone deacetylase inhibitors as a new generation of anti-cancer agents].

  Postepy higieny i medycyny doswiadczalnej (Online) 20050311

• Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.

  Bioorganic & medicinal chemistry letters 20050301

• Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

  Investigational new drugs 20050301

• 4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp.

  Journal of natural products 20050301

• Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.

  Nature clinical practice. Oncology 20050301

• Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

  Journal of medicinal chemistry 20050224

• Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.

  Bioorganic & medicinal chemistry letters 20050117

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.

  International journal of molecular medicine 20050101

• Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

  Experimental hematology 20050101

• High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.

  Rapid communications in mass spectrometry : RCM 20050101

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.

  Cancer research 20041201

• Histone deacetylase inhibitors up-regulate the expression of tight junction proteins.

  Molecular cancer research : MCR 20041201

• Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.

  The Journal of thoracic and cardiovascular surgery 20041101

• Subtype selective substrates for histone deacetylases.

  Journal of medicinal chemistry 20041007

• Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.

  Molecular pharmacology 20041001

• Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.

  Biochemical pharmacology 20040915

• Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.

  Journal of immunology (Baltimore, Md. : 1950) 20040915

• Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

  Apoptosis : an international journal on programmed cell death 20040901

• Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.

  Surgery 20040801

• Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.

  The Journal of biological chemistry 20040730

• Requirement of histone deacetylase activity for signaling by STAT1.

  The Journal of biological chemistry 20040716

• Suberanilohydroxamic Acid. Aton Pharma.

  IDrugs : the investigational drugs journal 20040701

• Thiol-based SAHA analogues as potent histone deacetylase inhibitors.

  Bioorganic & medicinal chemistry letters 20040621

• Role of oxidative enzymatic treatments on enzymatic hydrolysis of softwood.

  Biotechnology and bioengineering 20040605

• Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.

  Radiation research 20040601

• Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

  Journal of cellular biochemistry 20040515

• The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).

  Cell cycle (Georgetown, Tex.) 20040501

• [Therapeutic targets in polyglutamine diseases].

  Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20040501

• Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.

  International journal of oncology 20040401

• Silent advances.

  Environmental health perspectives 20040301

• QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.

  Bioorganic & medicinal chemistry letters 20040209

• Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.

  Cancer research 20031201

• The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

  Blood 20031115

• Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.

  Cancer research 20031101

• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030901

• Phosphorus-based SAHA analogues as histone deacetylase inhibitors.

  Organic letters 20030821

• Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

  Cancer research 20030801

• Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

  Blood 20030515

• Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors.

  International journal of cancer 20030501

• Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.

  Cancer research 20030501

• Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.

  Blood 20030415

• Anticancer drug shows promise against lupus.

  Drug discovery today 20030415

• Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).

  The Journal of biological chemistry 20030404

• Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.

  Blood 20030301

• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

  Proceedings of the National Academy of Sciences of the United States of America 20030218

• Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

  The Journal of clinical investigation 20030215

• Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice.

  Anticancer research 20030101

• One-step SFE-plus-C(18) selective extraction of low-polarity compounds, with lipid removal, from smoked fish and bovine milk.

  Analytical and bioanalytical chemistry 20021101

• The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.

  Experimental cell research 20020701

• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

  Leukemia 20020701

• Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.

  International journal of cancer 20020510

• Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

  Journal of medicinal chemistry 20020214

• Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.

  Oncogene 20020117

• Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

  Anticancer research 20020101

• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

  Cancer research 20011201

• Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?

  The Journal of clinical investigation 20011101

• Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.

  The Journal of clinical investigation 20011101

• Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).

  British journal of haematology 20011101

• The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

  Proceedings of the National Academy of Sciences of the United States of America 20010911

• Inhibitors of histone deacetylase are potentially effective anticancer agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

• Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.

  Breast cancer research : BCR 20010101

• Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

  Blood cells, molecules & diseases 20010101

• Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.

  Oncogene 20001123

• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.

  Oncogene 19991125